

Haematologica
HAEMATOL/2018/188987
Version 3

Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia

Timothy P. Hughes, Pierre Laneuville, Philippe Rousselot, David S. Snyder, Delphine Rea, Neil P. Shah, David Paar, Elisabetta Abruzzese, Andreas Hochhaus, Jeffrey H. Lipton, and Jorge E. Cortes

Disclosures: TPH, EA, and PL received research support from, served on scientific advisory boards of and consulted for ARIAD, Bristol-Myers Squibb, Pfizer, and Novartis; PL served as a speaker for ARIAD and Novartis. DSS served on advisory boards of ARIAD and Bristol-Myers Squibb, and is the institutional principal investigator for protocols sponsored by Bristol-Myers Squibb and Novartis. NPS received research funding from ARIAD, Bristol-Myers Squibb, Daiichi-Sankyo, Pfizer, and Plexxikon. AH received research funding from Bristol-Myers Squibb, Novartis, Incyte, and Pfizer. DP is an employee of Bristol-Myers Squibb. JHL received research funding from and is on advisory boards of ARIAD, Bristol-Myers Squibb, Novartis, and Pfizer. PR, DR, and JEC report nothing to disclose.

Contributions: All authors provided feedback and guidance on the analysis and interpretation of the results, critically reviewed the manuscript, and approved the final draft for submission.